Antonin L.
- Country
- France
- Department
- Service de radiothérapie
Research Overview
- Phase III Randomized Study of Immunotherapy and Local Ablative Treatments in Oligometastatic NSCLC: Evaluating Carboplatin, Ipilimumab, and Drug Combination
- Evaluation of Pembrolizumab, Chemotherapy, and Radiotherapy in Advanced Non-Small Cell Lung Cancer: A Randomized Controlled Trial
- Phase 2 Randomized Study of JNJ-90301900 with Chemoradiation and Durvalumab in Stage III Unresectable NSCLC
Data & Insights
Has run more than one trial at 13 of 54 partner sites.
Specializations
Lung Cancer Treatment
This investigator specializes in advanced therapeutic approaches for non-small cell lung cancer (NSCLC), with particular focus on integrating immunotherapy-based treatments with local interventions.
- Oligometastatic NSCLC Management
- Advanced Stage Treatment Protocols
- Local Ablative Therapies
The investigator explores innovative combinations of standard care protocols with targeted local treatments for enhanced patient outcomes.
Immunotherapy Applications
Expertise centers on the implementation of PD-(L)1 inhibitor therapies and their integration with various treatment modalities, particularly in combination with radiation therapy for advanced lung cancer.
- Combined Immunotherapy Approaches
- Radiation-Immunotherapy Protocols
- First-line Treatment Strategies
The research focuses on optimizing treatment outcomes through strategic combination of immunotherapeutic agents with conventional therapies.
Novel Therapeutic Development
Investigation of emerging treatments for locally advanced and unresectable Stage III NSCLC, incorporating innovative radioenhancers with established therapeutic protocols.
- Chemoradiation Enhancement
- Novel Drug Development
- Combined Modality Treatments
The investigator evaluates new therapeutic agents in combination with chemoradiation and immunotherapy for advanced lung cancer treatment.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.